Everything else in this library is a peptide that has to be injected, or a peptide put into a tablet with an absorption enhancer to survive the stomach. Orforglipron is neither. It is a small molecule that happens to act on the same receptor, which is a chemistry difference with practical consequences — no cold chain, no needle, no food-timing rules of the kind the existing pill requires, which we cover in what the pill actually does.
What the trial did
ATTAIN-1 was a phase 3, multinational, double-blind trial in adults who had obesity and did not have diabetes [1]. Patients were randomized in a 3:3:3:4 ratio to once-daily orforglipron at 6 mg, 12 mg or 36 mg, or to placebo, alongside diet and activity advice, for 72 weeks. The primary endpoint was percent change in body weight at week 72, analyzed in the intention-to-treat population.
What it found
Among the 3,127 patients randomized, mean weight change at 72 weeks was −7.5% (95% CI −8.2 to −6.8) at 6 mg, −8.4% (95% CI −9.1 to −7.7) at 12 mg and −11.2% (95% CI −12.0 to −10.4) at 36 mg, against −2.1% (95% CI −2.8 to −1.4) on placebo.
The thresholds are the more legible version of the same result. On 36 mg, 54.6% of patients lost 10% or more of their body weight, 36.0% lost 15% or more and 18.4% lost 20% or more. The placebo figures were 12.9%, 5.9% and 2.8%. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved against placebo as well.
What it costs in tolerability
Adverse events led to discontinuation in 5.3% to 10.3% of patients across the three orforglipron groups, against 2.7% on placebo. The most common were gastrointestinal and mostly mild to moderate — the same pattern the injected drugs produce, described in titration and nausea. The dose-response runs both ways: the arm that lost most weight was also the arm people left most often.
Where a reader will meet it
It is already being sold. Several storefronts tracked here list the branded tablet, usually routed through the manufacturer’s own pharmacy with a membership charged beside it, which makes the advertised medication figure only part of the bill. That structure is the subject of what sellers will not tell you, and the dose question applies here as much as anywhere: 36 mg is the dose that produced the headline, and a seller quoting a starter price is quoting a different rung. Which sellers publish the rungs at all is counted in who publishes a dose ladder.